1. 獎勵醫療機構之醫事人員從事臨床研究之受獎助醫師 (2005~2009) 2. 衛生署「卓越專科臨床試驗與研究中心五年企劃案」(2005~2009) 3. 國內外臨床試驗計畫主持人/共同主持人/協同主持人(2005~) (1) A phase III study to evaluate the impact of maintaining haemoglobin levels above 120g/L versus above 100g/L in anaemic patients with carcinoma of the cervix receiving concurrent cisplatin and radiation therapy Co-investigator (2) Retrospective international survey of human papillomavirus types in female genital tract neoplasia Co-investigator (3) Multi-national, open-label, phase I dose escalation study followed by randomized phase II study evaluating the efficacy and tolerability of pep02 with recurrent squamous carcinoma of the uterine cervix Co-investigator (4) Weekly topotecan chemotherapy in the treatment of recurrent ovarian cancer patients Co-investigator (5) Comparison of clinical outcomes, behavior modes and medical costs between women with or without HPV-related diseases and HPV vaccination in Tainan county Co-investigator (6) Phase III randomized trial of maintenance pegylated liposomal doxorubicin (PLD) / carboplatin versus without in patients with advanced ovarian cancer (TTYLD0512) Co-investigator (7) Phase III study of S-1 + cisplatin compared with single-agent cisplatin in stage IVb, recurrent or persistent carcinoma of the cervix (10020380-01) Co-investigator (8) A randomized, double-blind, placebo-controlled, phase 3 study to assess the efficacy and safety of weekly farletuzumab (MORAb-003) in combination with carboplatin and taxane in subjects with platinum-sensitive ovarian cancer in first relapse (MORAb-003-004) Co-investigator (9) Isolation and characterization of ovarian and lung cancer cells in body fluids: development of microfluidic systems for clinical applications Co-investigator (10) A pilot study to assess the efficacy and safety of topical SR-T100® gel in the treatment of human vagina, vulva, oral pre-cancerous lesions and cutaneous condyloma Co-investigator (11) Phase I trial of copper chelator in conjunction with pegylated liposomal doxorubicin and carboplatin in patients with platinum-resistant/-refractory epithelial ovarian cancer, tubal cancer and primary peritoneal cancer Co-investigator (12) A Phase 3, Multicenter, Randomized, Double‑Blind, Active-Controlled Study of the Safety and Efficacy of Rolapitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Subjects Receiving Highly Emetogenic Chemotherapy (HEC) Co-investigator (13) A Phase 3, Multicenter, Randomized, Double Blind, Active-Controlled Study of the Safety and Efficacy of Rolapitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Subjects Receiving Moderately Emetogenic Chemotherapy (MEC) Co-investigator (14) A phase 3, multicenter, randomized, open-label study of avelumab (MSB0010718C) alone or in combination with pegylated liposomal doxorubicin versus pegylated liposomal doxorubicin alone in patients with platinum-resistant/ refractory ovarian cancer (B9991009) Co-investigator (15) Phase 3 study of ADXS11-001 administered following chemoradiation as adjuvant treatment for high risk locally advanced cervical cancer: AIM2CERV (ADXS001-02) Co-investigator (16) An open, randomized, multi-center phase 2 trial of tamoxifen and letrozole in recurrent and persistent squamous cell carcinoma of the cervix：the efficacy and new biomarkers (A-BR-104-017) Co-investigator (17) A phase III, randomized, multi-center, double-blind, global study to determine the efficacy and safety of durvalumab in combination with and following chemoradiotherapy compared to chemoradiotherapy alone for treatment in women with locally advanced cervical cancer (CALLA) (D9100C00001) Co-investigator (18) An open-label, multicenter, phase ii study to evaluate the therapeutic activity of ro6874281, an immunocytokine, consisting of interleukin-2 variant (il-2v) targeting fibroblast activation protein-α (fap), in combination with atezolizumab (anti-pd-l1), administered intravenously, in participants with advanced and/or metastatic solid tumors (BP40234) Co-investigator (19) A phase 1/2, open-label, multi-center study of the safety and efficacy of KY1044 as single agent and in combination with anti-PD-L1 (atezolizumab) in adult patients with selected advanced malignancies (KY1044-CT01) Co-investigator (20) A randomized phase 3, double-blind study of chemotherapy with or without pembrolizumab followed by maintenance with olaparib or placebo for the first-line treatment of BRCA non-mutated advanced epithelial ovarian cancer (EOC) (MK7339-001/ENGOT-ov43/GOG-3036) Principle-investigator (21) A Phase 3, Double-Blind, Placebo-Controlled, Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) in Patients with Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma Principle-investigator 4. 執行NRPB補助主持人發起之臨床試驗計畫「具鉑抗藥性上皮性卵巢癌、輸卵管癌與原發性腹膜癌病人使用銅螫合劑輔助Pegylated Liposomal Doxorubicin合併Carboplatin治療之第一期臨床試驗」(2012~2018) 並發表卵巢癌轉譯醫學臨床試驗成果 (2019)